Pacific Biosciences of California, Inc. (PACB) Stock Forecast
PACB analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.88 / 5 from 8 analysts
- Price target
- $2.40 average of analyst targets
- Upside to target
- +38.7% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.13
- 52-week range
- $1.11 – $2.87
PACB analyst ratings
8 analystsNumber of analysts at each rating.
PACB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PACB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.14 | −$0.12 | −$0.12 | −9.2% | 7 |
| Current fiscal year (2026) | −$0.52 | −$0.53 | −$0.50 | −$0.53 | +2.3% | 7 |
| Next fiscal year (2027) | −$0.42 | −$0.52 | −$0.33 | −$0.52 | +18.6% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PACB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $39.5M | $37.4M | $41.7M | +2.6% | 6 |
| Current fiscal year (2026) | $158.7M | $153.3M | $162.0M | −0.8% | 6 |
| Next fiscal year (2027) | $184.1M | $173.7M | $198.7M | +16.0% | 7 |
PACB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PACB revenue: reported and forecast
PACB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.13 | −$0.13 | −$0.13 | −$0.13 | +3.1% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.51 | −$0.51 | −$0.51 | −$0.51 | −$0.52 | +2.3% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.40 | −$0.40 | −$0.40 | −$0.41 | −$0.42 | +6.3% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PACB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PACB beat in 11 of 12.
What analysts expect from PACB
8 analysts cover PacBio; their consensus rating is buy (3.88 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.40, 38.7% above the latest close of $1.73. Analysts expect earnings of −$0.52 per share for 2026, +2.3% from a year earlier. For 2027 the average estimate is −$0.42 per share on revenue of $184.1 million. PacBio beat the EPS estimate in 11 of the last 12 quarters.
Related: PACB income statement, PACB key metrics, PACB chart. See the PACB stock overview for the latest quote and news.
PACB forecast FAQ
What is PacBio's price target?
The average analyst price target for PacBio is $2.40, 38.7% above the latest close of $1.73.
Is PacBio a buy, hold or sell?
Of 8 analysts covering PacBio, 4 rate it a strong buy, 0 a buy, 3 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is PacBio's EPS forecast?
Analysts forecast −$0.52 per share for 2026 (range −$0.53 to −$0.50); for 2027 the estimate is −$0.42.
What is PacBio's revenue forecast?
The average revenue estimate for 2026 is $158.7 million, growth of −0.8%; for 2027 it is $184.1 million.
When does PacBio report earnings?
PacBio is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.13.
Does PacBio usually beat earnings estimates?
PacBio reported EPS at or above the analyst estimate in 11 of the last 12 quarters.